Dynavax Technologies Corporation (DVAX) : Traders are bullish on Dynavax Technologies Corporation (DVAX) as it has outperformed the S&P 500 by a wide margin of 5.6% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.85%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.82% in the last 1 week, and is up 6.01% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
Dynavax Technologies Corporation is up 3.37% in the last 3-month period. Year-to-Date the stock performance stands at -32.78%. The stock has recorded a 20-day Moving Average of 3.4% and the 50-Day Moving Average is 7.64%.
Dynavax Technologies Corporation (NASDAQ:DVAX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $16.07 and $15.83 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $16.43. The buying momentum continued till the end and the stock did not give up its gains. It closed at $16.24, notching a gain of 0.50% for the day. The total traded volume was 545,330 . The stock had closed at $16.16 on the previous day.
Also, Equity Analysts at the RBC Capital downgrades the rating on Dynavax Technologies Corporation (NASDAQ:DVAX). The brokerage firm has issued a Sector Perform rating on the shares. The shares were previously rated Outperform. The rating by the firm was issued on April 28, 2016.
Dynavax Technologies Corporation (Dynavax) is a clinical-stage biopharmaceutical company. The Company uses toll-like receptor (TLR) biology to discover and develop vaccines and therapeutics. Its development programs are organized under three areas of focus: vaccine adjuvants, cancer immunotherapy, and autoimmune and inflammatory diseases. The Companys pipeline of product candidates includes HEPLISAV-B, an investigational adult hepatitis B vaccine, is in Phase III clinical trials; SD-101, a cancer immunotherapy candidate, is in Phase I/II clinical trials; AZD1419, a candidate drug for asthma, is in Phase II clinical trials planning; DV1179 is an inhibitor of TLR 7 and TLR 9 for autoimmune and inflammatory diseases, is in Phase I clinical trials. DV230-Nanoparticle is a second generation adjuvant. DV230-Nanoparticle is in preclinical stage.